THOUSAND OAKS, Calif.--(March 30, 2004--Amgen Inc.
(Nasdaq:AMGN), the world´s largest biotechnology company, today
announced that Rodger Currie has been named vice president, Government
Affairs. Currie will work closely with David Beier, Amgen´s senior
vice president, Global Government Affairs, to create and design the
appropriate legislative strategy for the company, and will be
responsible for executing that strategy in Washington D.C.
Currie joins Amgen from Pharmaceutical Research & Manufacturers of
America (PhRMA), one of the largest and most influential lobbying
organizations in Washington, D.C., where he was most recently senior
vice president for Federal Affairs and Law. Currie led PhRMA´s
successful efforts to enact the Best Pharmaceuticals for Children Act
in 2001 (Public Law 107-109) to improve the safety and efficacy of
pharmaceuticals for children, and the Prescription Drug User Fee Act
in 2002 (Public Law 107-188), which re-authorized the U.S. Food and
Drug Administration (FDA) to collect fees from companies that produce
certain human drug and biological products, in exchange for FDA
agreement to meet drug-review performance goals that emphasize
timeliness. Currie also led the association´s efforts to pass $400
billion free market Medicare prescription drug coverage legislation,
including House and Senate passage of the PhRMA-supported bill. The
Hill named him "Top Lobbyist" in 2002, 2003 and 2004.
Prior to joining PhRMA, Currie worked as majority counsel for the
Committee on Energy & Commerce Republicans in the U.S. House of
Representatives, as an attorney in private practice and as a law clerk
in the U.S. Attorney´s Office. He earned his J.D. and B.A. degrees
from Georgetown University.
"With the ongoing importance of Amgen´s relationship to
legislative bodies and elected officials, Rodger will be the key asset
in the management of our Washington, D.C. office´s Federal Government
Affairs program, a vital initiative and a strategic imperative for
Amgen," said Beier.
Currie replaces Rita Norton, who has decided to retire from Amgen.
Norton will remain on staff over the next several months to ensure a
seamless transition, and has agreed to continue working with Amgen´s
Government Affairs team in a consulting role. Since joining Amgen in
1997, Norton has ably represented the company before the U.S. Congress
and Administrations on a wide variety of issues including tax,
intellectual property and Medicare and Medicaid reimbursement.
Amgen is a global biotechnology company that discovers, develops,
manufactures and markets important human therapeutics based on
advances in cellular and molecular biology.
CONTACT: Amgen, Thousand Oaks